Renibus Therapeutics initiates long-term study of Veverimer for CKD and metabolic acidosis
Renibus Therapeutics is conducting a 264-week study to assess the efficacy and safety of Veverimer in adults with moderate-to-severe CKD and metabolic acidosis.
Phase III
Chronic Kidney Disease market
Status
Active
Sponsor
Renibus Therapeutics
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The long-term study of Veverimer by Renibus Therapeutics could significantly impact the treatment landscape for chronic kidney disease and metabolic acidosis. Positive outcomes may enhance Renibus's competitive positioning and influence strategic partnerships within the nephrology sector.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results and final outcomes of the study, as well as any regulatory feedback during the trial.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.